View Older Stories View More Recent Stories

Aug 18, 2025 09:00AM Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
Aug 11, 2025 04:05PM Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 8, 2025 08:30AM Capricor schedules FDA meeting on Deramiocel regulatory path
Aug 8, 2025 08:30AM Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
Aug 6, 2025 09:00AM Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
Jul 28, 2025 09:00AM Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy
Jul 11, 2025 06:30AM Capricor receives FDA rejection for Duchenne muscular dystrophy treatment
Jul 11, 2025 06:30AM Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Jun 24, 2025 09:01AM Capricor Therapeutics (CAPR) Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Jun 24, 2025 09:00AM Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Jun 20, 2025 09:25AM Capricor Therapeutics (CAPR) Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Jun 20, 2025 09:25AM Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Jun 17, 2025 09:01AM Capricor Therapeutics (CAPR) Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
Jun 17, 2025 09:00AM Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
Jun 11, 2025 09:25AM Capricor Therapeutics (CAPR) Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
Jun 11, 2025 09:25AM Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
May 13, 2025 04:05PM Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025 09:01AM Capricor Therapeutics (CAPR) Appoints Michael Binks as Chief Medical Officer
May 13, 2025 09:00AM Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
May 6, 2025 09:15AM Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
May 5, 2025 08:06AM Capricor Therapeutics (CAPR) Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
May 5, 2025 08:00AM Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Apr 1, 2025 09:00AM Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day
Mar 19, 2025 04:05PM Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Mar 17, 2025 09:25AM Capricor Therapeutics (CAPR) Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel
Mar 17, 2025 09:25AM Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Mar 11, 2025 09:00AM Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
Mar 7, 2025 09:25AM Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
Mar 4, 2025 07:02AM Capricor Therapeutics (CAPR) Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Mar 4, 2025 07:00AM Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Feb 10, 2025 09:00AM Capricor Therapeutics to Participate in Upcoming Investor Conferences
Jan 2, 2025 09:15AM Capricor Therapeutics (CAPR) Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel
Jan 2, 2025 09:15AM Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Dec 2, 2024 04:15PM Capricor Therapeutics to Present at Upcoming Investor Conferences
Nov 20, 2024 09:02AM Capricor Therapeutics (CAPR) Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
Nov 20, 2024 09:00AM Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
Nov 13, 2024 04:01PM Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 12, 2024 09:00AM Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting
Nov 5, 2024 09:00AM Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
Oct 18, 2024 04:01PM Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Oct 17, 2024 06:00AM Capricor Therapeutics (CAPR) Prices $75M Share Offering at $17/sh
Oct 17, 2024 06:00AM Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
Oct 16, 2024 04:18PM Capricor Therapeutics (CAPR) Announces Proposed Public Offering of Common Stock
Oct 16, 2024 04:17PM Capricor Therapeutics Announces Proposed Public Offering of Common Stock
Oct 11, 2024 09:15AM Capricor Therapeutics (CAPR) Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
Oct 11, 2024 09:15AM Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
Oct 9, 2024 09:15AM Capricor Therapeutics (CAPR) Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of DMD
Oct 9, 2024 09:15AM Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Oct 4, 2024 09:15AM Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
Sep 24, 2024 08:01AM Capricor Therapeutics (CAPR) Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
View More Recent Stories View Older Stories